fda safety communication semaglutide naion 2025 Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or Semaglutide-associated risk of nonarteritic anterior

The first biosimilar formulation of a GLP-1 receptor agonist, liraglutide, has recently been marketed, at a lower acquisition cost than the original formulation, whilst oral semaglutide remains the only currently available GLP-1 receptor agonist that is administered orally

This move supports the companys goal of expanding its treatment options for people living with obesity.

In 4 simple steps, you can start losing up to 12% of body weight with a healthy lifestyle and GLP-1 agonists

ByDrug 2025-09-12 13:40 API copycat compounded drugs 2025 9 FDA Import Alert 66-80 Green List GLP-1 API ...

For years, Ozempic has been widely recognized as a once weekly injectable medication

A stably transfected Chinese hamster ovary cell line was obtained using electroporation